<p>Enovis Co. (NYSE:ENOV - 獲取免費報告) 的股價在週四的午盤交易中創下 52 周新低，此前 Needham &amp; Company LLC 將其目標價從 65.00 美元下調至 64.00 美元。Needham &amp; Company LLC 目前對該股票維持買入評級。Enovis 的股價最低曾達到 38.17 美元，最後交易價為 38.25 美元，成交量為 725459 股。該股票此前收盤價為 40.00 美元。</p>
<h2>機構資金流入和流出</h2>
<p>一些機構投資者和對沖基金最近買入和賣出了 ENOV 的股票。Raymond James &amp; Associates 在第三季度將其在 Enovis 的持股增加了 1076.7%。Raymond James &amp; Associates 目前擁有 56,692 股該公司的股票，價值 2,441,000 美元，此前在該期間購買了 51,874 股。路易斯安那州員工退休系統在第三季度將其在 Enovis 的股份增加了 9.9%。路易斯安那州員工退休系統目前擁有 15,500 股該公司的股票，價值 667,000 美元，此前在上個季度購買了 1,400 股。DekaBank Deutsche Girozentrale 在第三季度新建了一個價值約 55,000 美元的 Enovis 頭寸。阿拉斯加州收入部在第三季度將其在 Enovis 的股份增加了 20.8%。阿拉斯加州收入部目前擁有 6,482 股該公司的股票，價值 279,000 美元，此前在上個季度購買了 1,115 股。最後，US Bancorp DE 在第三季度將其在 Enovis 的持股增加了 29.1%。US Bancorp DE 目前擁有 17,962 股該公司的股票，價值 773,000 美元，此前在該期間購買了 4,050 股。對沖基金和其他機構投資者持有該公司 98.45% 的股票。</p>
<h2>Enovis 價格表現</h2>
<p>該公司的流動比率為 2.27，速動比率為 1.12，債務與股本比率為 0.40。該公司的市值為 21.7 億美元，市盈率為-17.42，貝塔值為 1.94。該公司的 50 日移動平均線為 44.90 美元，200 日移動平均線為 44.34 美元。</p>
<p>Enovis (NYSE:ENOV - 獲取免費報告) 最近在 2 月 26 日星期三發佈了季度財報。該公司報告季度每股收益為 0.98 美元，超出市場普遍預期的 0.92 美元，超出幅度為 0.06 美元。該公司季度收入為 5.6098 億美元，而分析師預期為 5.5514 億美元。Enovis 的淨利潤率為-5.95%，股本回報率為 4.39%。整體來看，分析師預測 Enovis Co.在當前年度將發佈 2.79 美元的每股收益。</p>
<h2>Enovis 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Enovis Corporation 是一家醫療技術公司，專注於開發臨牀差異化的解決方案，業務遍及全球。它還製造和分銷用於重建手術、康復、疼痛管理和物理治療的醫療設備。該公司通過預防與恢復和重建兩個部門運營。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票比 Enovis 更好</li>
<li>賣空：如何做空一隻股票</li>
<li>波動性迴歸：3 只股票可以緩衝標準普爾 500 的波動</li>
<li>股息捕捉策略：你需要知道的事項</li>
<li>可能推動 NVIDIA 股票上漲 30% 的兩個催化劑</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>通用汽車股票回購是否使股票對投資者可買？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Enovis 嗎？</h2>
<p>在你考慮 Enovis 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Enovis 並不在名單上。</p>
<p>雖然 Enovis 目前在分析師中獲得中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

ENOV

<p>Enovis (NYSE:ENOV) 達到新的 52 周低點 38.17 美元，此前 Needham & Company 將其目標價從 65.00 美元下調至 64.00 美元，但維持買入評級。該股收盤價為 38.25 美元，交易量為 725,459 股。機構投資者持有 98.45% 的股份，其中 Raymond James & Associates 等的持股顯著增加。Enovis 報告上個季度每股收益為 0.98 美元，超出預期，收入為 5.6098 億美元。分析師預測當前年度每股收益為 2.79 美元</p>

<p>Enovis Co. (NYSE:ENOV - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Thursday after Needham &amp; Company LLC lowered their price target on the stock from $65.00 to $64.00. Needham &amp; Company LLC currently has a buy rating on the stock. Enovis traded as low as $38.17 and last traded at $38.25, with a volume of 725459 shares. The stock had previously closed at $40.00.</p>
<div class="lb-trans"><p>Enovis Co. (NYSE:ENOV - 獲取免費報告) 的股價在週四的午盤交易中創下 52 周新低，此前 Needham &amp; Company LLC 將其目標價從 65.00 美元下調至 64.00 美元。Needham &amp; Company LLC 目前對該股票維持買入評級。Enovis 的股價最低曾達到 38.17 美元，最後交易價為 38.25 美元，成交量為 725459 股。該股票此前收盤價為 40.00 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of ENOV. Raymond James &amp; Associates raised its holdings in shares of Enovis by 1,076.7% during the third quarter. Raymond James &amp; Associates now owns 56,692 shares of the company's stock worth $2,441,000 after purchasing an additional 51,874 shares during the period. Louisiana State Employees Retirement System grew its stake in shares of Enovis by 9.9% in the third quarter. Louisiana State Employees Retirement System now owns 15,500 shares of the company's stock worth $667,000 after purchasing an additional 1,400 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in Enovis during the 3rd quarter valued at about $55,000. State of Alaska Department of Revenue boosted its stake in Enovis by 20.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,482 shares of the company's stock valued at $279,000 after purchasing an additional 1,115 shares in the last quarter. Finally, US Bancorp DE grew its holdings in Enovis by 29.1% during the third quarter. US Bancorp DE now owns 17,962 shares of the company's stock worth $773,000 after acquiring an additional 4,050 shares during the period. Hedge funds and other institutional investors own 98.45% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近買入和賣出了 ENOV 的股票。Raymond James &amp; Associates 在第三季度將其在 Enovis 的持股增加了 1076.7%。Raymond James &amp; Associates 目前擁有 56,692 股該公司的股票，價值 2,441,000 美元，此前在該期間購買了 51,874 股。路易斯安那州員工退休系統在第三季度將其在 Enovis 的股份增加了 9.9%。路易斯安那州員工退休系統目前擁有 15,500 股該公司的股票，價值 667,000 美元，此前在上個季度購買了 1,400 股。DekaBank Deutsche Girozentrale 在第三季度新建了一個價值約 55,000 美元的 Enovis 頭寸。阿拉斯加州收入部在第三季度將其在 Enovis 的股份增加了 20.8%。阿拉斯加州收入部目前擁有 6,482 股該公司的股票，價值 279,000 美元，此前在上個季度購買了 1,115 股。最後，US Bancorp DE 在第三季度將其在 Enovis 的持股增加了 29.1%。US Bancorp DE 目前擁有 17,962 股該公司的股票，價值 773,000 美元，此前在該期間購買了 4,050 股。對沖基金和其他機構投資者持有該公司 98.45% 的股票。</p>
</div><h2>Enovis Price Performance</h2>
<div class="lb-trans"><h2>Enovis 價格表現</h2>
</div><p>The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $2.17 billion, a P/E ratio of -17.42 and a beta of 1.94. The business's fifty day moving average is $44.90 and its 200 day moving average is $44.34.</p>
<div class="lb-trans"><p>該公司的流動比率為 2.27，速動比率為 1.12，債務與股本比率為 0.40。該公司的市值為 21.7 億美元，市盈率為-17.42，貝塔值為 1.94。該公司的 50 日移動平均線為 44.90 美元，200 日移動平均線為 44.34 美元。</p>
</div><p>Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.06. The firm had revenue of $560.98 million for the quarter, compared to analysts' expectations of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. As a group, analysts forecast that Enovis Co. will post 2.79 EPS for the current year.</p>
<div class="lb-trans"><p>Enovis (NYSE:ENOV - 獲取免費報告) 最近在 2 月 26 日星期三發佈了季度財報。該公司報告季度每股收益為 0.98 美元，超出市場普遍預期的 0.92 美元，超出幅度為 0.06 美元。該公司季度收入為 5.6098 億美元，而分析師預期為 5.5514 億美元。Enovis 的淨利潤率為-5.95%，股本回報率為 4.39%。整體來看，分析師預測 Enovis Co.在當前年度將發佈 2.79 美元的每股收益。</p>
</div><h2>Enovis Company Profile</h2>
<div class="lb-trans"><h2>Enovis 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.</p>
<div class="lb-trans"><p>Enovis Corporation 是一家醫療技術公司，專注於開發臨牀差異化的解決方案，業務遍及全球。它還製造和分銷用於重建手術、康復、疼痛管理和物理治療的醫療設備。該公司通過預防與恢復和重建兩個部門運營。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Enovis</li>
<li>Short Selling: How to Short a Stock</li>
<li>Volatility Is Back: 3 Stocks To Cushion the S&amp;P 500's Swings</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>2 Catalysts That Could Push NVIDIA Stock Up 30% This Year</li>
<li>What is a buyback in stocks? A comprehensive guide for investors</li>
<li>Do GM Stock Buybacks Make the Stock Buyable For Investors?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Enovis 更好</li>
<li>賣空：如何做空一隻股票</li>
<li>波動性迴歸：3 只股票可以緩衝標準普爾 500 的波動</li>
<li>股息捕捉策略：你需要知道的事項</li>
<li>可能推動 NVIDIA 股票上漲 30% 的兩個催化劑</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>通用汽車股票回購是否使股票對投資者可買？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Enovis Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Enovis 嗎？</h2>
</div><p>Before you consider Enovis, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Enovis 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Enovis 並不在名單上。</p>
</div><p>While Enovis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Enovis 目前在分析師中獲得中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Enovis（紐約證券交易所代碼：ENOV）因分析師下調評級創下一年新低